Pisoni RL, et al.. Pruritus in haemodialysis patients: International results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2006; 21:3495−3505. doi: 10.1093/ndt/gfl461

• Crossref
Pisoni RL, . Pruritus in haemodialysis patients: International results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2006; 21:3495−3505. doi: 10.1093/ndt/gfl46110.1093/ndt/gfl461)| false
• Search Google Scholar
• Export Citation

Zucker I, et al.. Prevalence and characterization of uremic pruritus in patients undergoing hemodialysis: Uremic pruritus is still a major problem for patients with end-stage renal disease. J Am Acad Dermatol 2003; 49:842−846. doi: 10.1016/s0190-9622(03)02478-2

• Crossref
Zucker I, . Prevalence and characterization of uremic pruritus in patients undergoing hemodialysis: Uremic pruritus is still a major problem for patients with end-stage renal disease. J Am Acad Dermatol 2003; 49:842−846. doi: 10.1016/s0190-9622(03)02478-210.1016/S0190-9622(03)02478-2)| false
• Search Google Scholar
• Export Citation

Rayner HC, et al.. International comparisons of prevalence, awareness, and treatment of pruritus in people on hemodialysis. Clin J Am Soc Nephrol 2017; 12:2000−2007. doi: 10.2215/CJN.03280317

• Crossref
Rayner HC, . International comparisons of prevalence, awareness, and treatment of pruritus in people on hemodialysis. Clin J Am Soc Nephrol 2017; 12:2000−2007. doi: 10.2215/CJN.0328031710.2215/CJN.03280317)| false
• Search Google Scholar
• Export Citation

Martin CE, et al.. Have we just scratched the surface? A narrative review of uremic pruritus in 2020. Can J Kidney Health Dis 2020; 7:2054358120954024. doi:

• Crossref
Martin CE, . Have we just scratched the surface? A narrative review of uremic pruritus in 2020. Can J Kidney Health Dis 2020; 7:2054358120954024. doi:10.1177/2054358120954024)| false
• Search Google Scholar
• Export Citation

Simonsen E, et al.. Treatment of uremic pruritus: A systematic review. Am J Kidney Dis 2017; 70:638−655. doi: 10.1053/j.ajkd.2017.05.018

• Crossref
Simonsen E, . Treatment of uremic pruritus: A systematic review. Am J Kidney Dis 2017; 70:638−655. doi: 10.1053/j.ajkd.2017.05.01810.1053/j.ajkd.2017.05.018)| false
• Search Google Scholar
• Export Citation

Chou F-F, et al.. A study on pruritus after parathyroidectomy for secondary hyperparathyroidism 1. J Am Coll Surg 2000; 190:65−70. doi: 10.1016/s1072-7515(99)00212-4

• Crossref
Chou F-F, . A study on pruritus after parathyroidectomy for secondary hyperparathyroidism 1. J Am Coll Surg 2000; 190:65−70. doi: 10.1016/s1072-7515(99)00212-410.1016/S1072-7515(99)00212-4)| false
• Search Google Scholar
• Export Citation

Duque MI, et al.. Lack of efficacy of tacrolimus ointment 0.1% for treatment of hemodialysis-related pruritus: A randomized, double-blind, vehicle-controlled study. J Am Acad Dermatol 2005; 52 (3 Pt 1):519−521. doi: 10.1016/j.jaad.2004.08.050

• Crossref
Duque MI, . Lack of efficacy of tacrolimus ointment 0.1% for treatment of hemodialysis-related pruritus: A randomized, double-blind, vehicle-controlled study. J Am Acad Dermatol 2005; 52 (3 Pt 1):519−521. doi: 10.1016/j.jaad.2004.08.05010.1016/j.jaad.2004.08.050)| false
• Search Google Scholar
• Export Citation

US Food and Drug Administration. FDA Approves Updated Labeling with Boxed Warning and Medication Guide for Two Eczema Drugs, Elidel and Protopic. January 19, 2006. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-approves-updated-labeling-boxed-warning-and-medication-guide-two-eczema-drugs-elidel-and

US Food and Drug Administration. FDA Approves Updated Labeling with Boxed Warning and Medication Guide for Two Eczema Drugs, Elidel and Protopic. January 19, 2006. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-approves-updated-labeling-boxed-warning-and-medication-guide-two-eczema-drugs-elidel-and)| false
• Search Google Scholar
• Export Citation

Ishida JH, et al.. Gabapentin and pregabalin use and association with adverse outcomes among hemodialysis patients. J Am Soc Nephrol 2018; 29:1970−1978. doi: 10.1681/ASN.2018010096

• Crossref
Ishida JH, . Gabapentin and pregabalin use and association with adverse outcomes among hemodialysis patients. J Am Soc Nephrol 2018; 29:1970−1978. doi: 10.1681/ASN.201801009610.1681/ASN.2018010096)| false
• Search Google Scholar
• Export Citation

Pauli-Magnus C, et al.. Naltrexone does not relieve uremic pruritus. Results of a randomized, double-blind, placebo-controlled crossover study. J Am Soc Nephrol 2000; 11:514−519. https://jasn.asnjournals.org/content/11/3/514

Pauli-Magnus C, . Naltrexone does not relieve uremic pruritus. Results of a randomized, double-blind, placebo-controlled crossover study. J Am Soc Nephrol 2000; 11:514−519. https://jasn.asnjournals.org/content/11/3/514)| false
• Search Google Scholar
• Export Citation

Legroux-Crespel E, et al.. A comparative study on the effects of naltrexone and loratadine on uremic pruritus. Dermatology 2004; 208:326−330. doi: 10.1159/000077841

• Crossref
Legroux-Crespel E, . A comparative study on the effects of naltrexone and loratadine on uremic pruritus. Dermatology 2004; 208:326−330. doi: 10.1159/00007784110.1159/000077841)| false
• Search Google Scholar
• Export Citation

Inui S Nalfurafine hydrochloride to treat pruritus: A review. Clin Cosmet Investig Dermatol 2015; 8:249−255. doi: 10.2147/CCID.S55942

• Crossref
Inui S Nalfurafine hydrochloride to treat pruritus: A review. Clin Cosmet Investig Dermatol 2015; 8:249−255. doi: 10.2147/CCID.S5594210.2147/CCID.S55942)| false
• Search Google Scholar
• Export Citation

Sumitomo Dainippon Pharma Co., Ltd. IR News: Toray's Pruritus Treatment REMITCH OD Tablets 2.5 μg to Be Introduced in Japan. May 31, 2017. https://www.ds-pharma.com/ir/news/2017/20170531.html

Sumitomo Dainippon Pharma Co., Ltd. IR News: Toray's Pruritus Treatment REMITCH OD Tablets 2.5 μg to Be Introduced in Japan. May 31, 2017. https://www.ds-pharma.com/ir/news/2017/20170531.html)| false
• Search Google Scholar
• Export Citation

Fishbane S, et al.. A phase 3 trial of difelikefalin in hemodialysis patients with pruritus. N Engl J Med 2020; 382:222−232. doi: 10.1056/NEJMoa1912770

• Crossref
Fishbane S, . A phase 3 trial of difelikefalin in hemodialysis patients with pruritus. N Engl J Med 2020; 382:222−232. doi: 10.1056/NEJMoa191277010.1056/NEJMoa1912770)| false
• Search Google Scholar
• Export Citation

Mathur VS, et al.. A multicenter, randomized, double-blind, placebo-controlled trial of nalbuphine ER tablets for uremic pruritus. Am J Nephrol 2017; 46:450−458. doi: 10.1159/000484573

• Crossref
Mathur VS, . A multicenter, randomized, double-blind, placebo-controlled trial of nalbuphine ER tablets for uremic pruritus. Am J Nephrol 2017; 46:450−458. doi: 10.1159/00048457310.1159/000484573)| false
• Search Google Scholar
• Export Citation

Endo Pharmaceuticals Inc. NUBAIN (Nalbuphine Hydrochloride). January 2005. https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/018024s040lbl.pdf

Endo Pharmaceuticals Inc. NUBAIN (Nalbuphine Hydrochloride). January 2005. https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/018024s040lbl.pdf)| false
• Search Google Scholar
• Export Citation